Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICARIA-MM: Isatuximab + Pomalidomide + Dexamethasone in RRMM
NCT02990338Phase 3Completed
- Sponsor
- Sanofi
- Start
- Dec 2016
- Primary completion
- Nov 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial of isatuximab in multiple myeloma (MM) (2 arms), sponsored by Sanofi. Primary endpoint: Progression Free Survival up to 76.7 weeks. Started Dec 2016; status: completed.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02990338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02990338.